



JEA BizDev Consulting Advises CSPC on Strategic Partnership with Cipla USA

CLIENT SHOWCASE

May 15, 2025

On May 15, 2025, CSPC Pharmaceutical Group Limited together with its subsidiaries (CSPC) announced that it has entered into an exclusive license agreement with Cipla USA, Inc., for the commercialization of its Irinotecan Liposomal Injection in the United States. [JEA BizDev Consulting, LLC](#) acted as Lead Business Development and Transaction Advisor to CSPC on the strategic partnership.

Under the terms of the agreement, CSPC will receive an upfront payment of US\$15 million and up to US\$1,050 million in potential regulatory and commercial milestones, in addition to tiered double-digit royalties based on annual net sales.

The JEA BizDev Consulting team advising CSPC was led by [John Adamou](#), President and Managing Director.

For more information, please see CSPC's voluntary announcement [news release](#).